Table 1 Characteristics of included studies
Author | Year | Country | Study design | Setting | Treatment | Sample size (n) | Run-in phase | Follow-up | Gender (M/F number) | Age (y) | PLA2Rabpositivity N (%) | PLA2Rab level (RU/ml) | Baseline proteinuria (g/d) | eGFR (ml/min/m2) | Scr (mg/dl) | Serum albumin (g/dl) | PLA2Rab assay company |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medrano [18] | 2014 | Spain | P | S | RTX + TAC | 53 | 3 months | 12 months | 31/22 | 51.1 ± 14.2 | 53 (100) | 239.8 ± 86 | 12.3 ± 3.6 | 91.6 ± 29.2 | 0.9 ± 0.4 | 2.2 ± 0.5 | Euroimmune, Lubeck, Germany |
CYC + CS | 26 | 18/8 | 51.8 ± 17.3 | 26 (100) | 259 ± 89 | 11.9 ± 4.7 | 89.5 ± 36.3 | 1.0 ± 0.2 | 2.2 ± 0.4 | ||||||||
van den Brand [15] | 2017 | Netherlands and Italy | R | M | RTX | 100 | 6 months | 60 months | 72/28 | 51.5 ± 15.9 | NA | NA | 6.4(4.4–8.9) | 59.1 (26.6) | 1.2 (1.0–1.7) | 2.2 (0.7) | NA |
CYC + CS | 103 | 76/27 | 55.3 ± 12.7 | NA | NA | 8.8 (5.7–11.7) | 58.4 (22.8) | 1.3 (1.0–1.6) | 2.2 (0.7) | ||||||||
Fenoglio [17] | 2020 | Italy | R | S | RTX low | 14 | 6 months | 24 months | 9/5 | 64.4 ± 10.8 | NA | NA | 7.5 ± 4.8 | 68.7 ± 26.6 | 1.05 ± 0.34 | 2.5 ± 0.5 | NA |
RTX standard | 14 | 5/9 | 61.4 ± 11.5 | NA | NA | 5.1 ± 1.4 | 75.8 ± 29.8 | 1.06 ± 0.46 | 2.6 ± 0.6 | ||||||||
CYC + CS | 14 | 8/6 | 67.1 ± 17.5 | NA | NA | 8.3 ± 4.8 | 80.8 ± 29 | 1.3 ± 0.9 | 2.4 ± 0.5 | ||||||||
Fernandez-Juarez [13] | 2020 | Spain and Netherlands | RCT | M | RTX + TAC | 43 | 6 months | 24 months | 31/12 | 55.2 ± 10.8 | 24/32 (75) | 113 (61–151) | 7.4 (6.7–11.6) | 79.1 ± 25.5 | 1.0 ± 0.28 | 2.6 (2.0–2.9) | Euroimmune, Lubeck, Germany |
CYC + CS | 43 | 24/19 | 56.2 ± 12.0 | 29/37 (78) | 59 (37–150) | 7.4 (4.8–11.3) | 80.5 ± 21.6 | 1.0 ± 0.3 | 2.6 (2.3–2.9) | ||||||||
Scolari [14] | 2021 | Italy and Switzerland | RCT | M | RTX | 37 | 3 months | 36 months | 28/9 | 54 (14) | 22 (73) | 63 (52–87) | 6 (4–10) | 83 (24) | 1 (0) | 2 (1) | Euroimmune, Lubeck, Germany |
‘ | CYC + CS | 37 | 25/12 | 55 (17) | 19 (59) | 58 (40–81) | 6 (5–9) | 86 (25) | 1 (0) | 2 (1) | |||||||
Ramachandran [16] | 2021 | India | P | S | RTX | 13 | NA | 24 months | 10/3 | 52 (36.5–59.5) | NA | 194 (90–866) | 7.9 (4.5–13.5) | 37 (35–50.6) | 1.6 (1.5–2) | 2.4 (1.8–2.8) | Euroimmune, Lubeck, German |
CYC + CS | 49 | 38/11 | 48 (41–55) | NA | 126 (18–271) | 5.2 (4–8) | 42.5 (32–49) | 1.7 (1.5–2.2) | 2.5 (1.9–3.1) | ||||||||
Hussain [19] | 2022 | United Kingdom | R | S | RTX or CYC | 50 | NA | 12 months | 30/20 | 53 | 18 (32) | NA | NA | NA | NA | NA | NA |
Zhou [20] | 2022 | China | R | S | RTX | 16 | 3 months | 24 months | 10/6 | 50 ± 10 | 16 (100) | 210 ± 59 | 6.5 ± 4.2 | 72 ± 25 | NA | NA | NA |
CYC + CS | 20 | 11/9 | 52 ± 11 | 20 (100) | 233 ± 62 | 5.6 ± 1.5 | 73 ± 33 | NA | NA |